Xcout Intel
Azalea Therapeutics
Azalea Therapeutics is a biotechnology company headquartered in Berkeley, California. The company focuses on precision genome engineering directly inside the body with an initial emphasis on developing in vivo cancer immunotherapies.
Subscribe to see Azalea Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Azalea Therapeutics at a glance
Azalea Therapeutics is a biotech company headquartered in United States. It has raised at least $82M across the 2 funding rounds on record. Its most recent funding round, Series A, raised $65M in November 2025. Xcout tracks 15 named people at Azalea Therapeutics, including Jenny Hamilton (Co-founder, President and Chief Executive Officer).
Azalea Therapeutics leadership
- Jenny HamiltonCo-founder, President and Chief Executive Officer
- Paul WestbergChief Business Officer
- Jenny Hamiltonco-founder, president and chief executive officer
- Abdullah Syedscientific co-founder
- Connor Tsuchidascientific co-founder
- Jennifer Doudnaco-founder
9 more named people on record for Azalea Therapeutics, with roles, board committees and tenure — see the full roster →
Azalea Therapeutics funding rounds
At least $82M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $65M | 4 named | |
| — | $17M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Azalea Therapeutics competitors
A few of Azalea Therapeutics's closest competitors — see the full list of competitors and alternatives →
Prime Medicine, Inc. is an American biotechnology company developing gene therapies based on prime editing. The company is headquartered in Cambridge, Massachusetts.
Ray Therapeutics, Inc. is a privately held optogenetic gene therapy company headquartered in Berkeley, California. The company focuses on reimagining vision through innovative genetic treatments and novel therapeutic solutions.
Base Therapeutics is a biotechnology company that develops next-generation gene editing technologies, including its proprietary AccuBase base editing system and enhanced prime editing technology. The company focuses on creating therapeutic solutions for cancer and genetic diseases, alongside engineered immune cell therapies such as BASE-NK and CAR-T products. It serves patients and partners with pharmaceutical and agricultural enterprises by licensing its precision gene editing tools.
Tessera Therapeutics is a biotechnology company developing programmable genetic medicines using its Gene Writing technology, which is based on mobile genetic elements to insert, replace, or modify DNA in cells. It aims to develop treatments for genetic diseases and other serious conditions, serving patients who need durable genetic therapies.
GeneTether, Inc., also known as Rize Oncology, is a biotechnology company headquartered in San Lorenzo, California, focused on developing proprietary gene-editing technologies and targeted oncology therapeutics.
Acrigen Biosciences, Inc. is a biotechnology company headquartered in California, United States. The firm is developing precision gene editing systems and delivery technologies to control CRISPR applications and provide advanced genetic medicines. Its research is conducted in collaboration with academic groups such as UCSF.
Get Azalea Therapeutics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Azalea Therapeutics in Xcout Intel
- 15 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access